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Background. Serial cross-sectional data on antibody levels to the 2009 pandemic H1N1 influenza A virus from
a population can be used to estimate the infection attack rates and immunity against future infection in the
community.
Methods. From April through December 2009, we obtained 12,217 serum specimens from blood donors (aged
16–59 years), 2520 specimens from hospital outpatients (aged 5–59 years), and 917 specimens from subjects
involved in a community pediatric cohort study (aged 5–14 years). We estimated infection attack rates by comparing
the proportions of specimens with antibody titers 1:40 by viral microneutralization before and after the first
wave of the pandemic. Estimates were validated using paired serum samples from 324 individuals that spanned
the first wave. Combining these estimates with epidemiologic surveillance data, we calculated the proportion of
infections that led to hospitalization, admission to the intensive care unit (ICU), and death.
Results. We found that 3.3% and 14% of persons aged 5–59 years had antibody titers 1:40 before and after
the first wave, respectively. The overall attack rate was 10.7%, with age stratification as follows: 43.4% in persons
aged 5–14 years, 15.8% in persons aged 15–19 years, 11.8% in persons aged 20–29 years, and 4%–4.6% in persons
aged 30–59 years. Case-hospitalization rates were 0.47%–0.87% among persons aged 5–59 years. Case-ICU rates
were 7.9 cases per 100,000 infections in persons aged 5–14 years and 75 cases per 100,000 infections in persons
aged 50–59 years, respectively. Case-fatality rates were 0.4 cases per 100,000 infections in persons aged 5–14 years
and 26.5 cases per 100,000 infections in persons aged 50–59 years, respectively.
Conclusions. Almost half of all school-aged children in Hong Kong were infected during the first wave.
Compared with school children aged 5–14 years, older adults aged 50–59 years had 9.5 and 66 times higher risks
of ICU admission and death if infected, respectively.
The 2009 pandemic influenza A H1N1 virus emerged
in Mexico in early 2009 and rapidly spread around the
world [1]. By January 2010, most countries had ex-
perienced at least one substantial epidemic wave. Vac-
cines against the novel H1N1 influenza strain became
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available toward the end of 2009. Timely serologic data
are important to facilitate identification of the target
groups for whom pandemic vaccine would be most
useful prior to subsequent waves, because some pop-
ulation groups may have substantial immunity follow-
ing the first wave. We conducted a prospective sero-
epidemiological study using serial cross-sectional data
as well as longitudinal cohort data to estimate age-
specific H1N1 influenza infection attack rates (IARs)
in the community during the first wave of the pan-
demic. We used our IAR estimates to infer the severity
of the pandemic strain, including the age-specific pro-
portion of infections that led to laboratory confirma-
tion, hospitalization, intensive care unit (ICU) admis-
sion, and death [2–5].
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METHODS
Subjects
Blood donors, aged 16–65 years. From 12 June through 31
December 2009, blood donors from the 4 largest blood do-
nation centers (Mongkok, Causeway Bay, Kwun Tong, and
Tsuen Wan) of the Hong Kong Red Cross Blood Transfusion
Service were invited to participate in our serologic surveillance
study. Eligible donors were healthy adults aged 16–65 years and
weighing 141 kg. Repeated participants were identified using
their unique Blood Transfusion Service identification numbers.
A total of 12,217 serum samples were tested. Paired serum
specimens from before the first pandemic wave (before 1 Au-
gust 2009) and after the first pandemic wave (after 15 Novem-
ber 2009) were collected from 324 blood donors. Blood donors
did not receive any remuneration or compensation.
Hospital outpatients, aged 5–59 years. From 2 September
through 31 December 2009, we invited patients visiting the
Pediatric and Adolescent Medicine outpatient clinic and the
Medicine outpatient clinic at Queen Mary Hospital to partic-
ipate in our serologic surveillance study. Patients with acute
respiratory infections or immunosuppression (including pa-
tients receiving chemotherapy for various malignancies, post-
transplant or cirrhotic patients, or any patients receiving sys-
temic immunosuppressants) at recruitment were excluded from
participation. A total of 2520 serum samples were tested.
Subjects of a community study, aged 5–14 years. From 1
November 2008 through 31 October 2009, we conducted a
cohort study of pediatric seasonal influenza vaccination and
household transmission of influenza. A total of 151 children
aged 5–14 years were recruited and provided baseline serum
samples in November and December 2008. From September
through December 2009, an additional 766 children aged 5–
14 years were recruited and provided baseline serum samples
for the second phase of the study. For the present study, we
tested the 151 serum samples collected before the first pandemic
wave and the 766 serum samples collected after the first wave.
Informed Consent
Written informed consent was obtained from all participants.
Parental consent was obtained for participants aged15 years,
and children aged 8–15 years gave written assent. All study
protocols were approved by the Institutional Review Board of
the University of Hong Kong/Hospital Authority Hong Kong
West Cluster.
Data on Hospitalization, ICU Admission, and Death
Age-stratified data on virologically confirmed outpatient con-
sultations, hospitalizations, ICU admissions, and deaths associ-
ated with H1N1 influenza from 29 April 2009 through 15 No-
vember 2009 were provided by the Hong Kong Hospital Au-
thority (the e-flu database) [6]. From May 2009 onward, patients
admitted with acute respiratory illnesses routinely underwent
laboratory testing for H1N1 influenza virus by molecular meth-
ods. Population-size data by age were obtained from the Hong
Kong Government Census and Statistics Department.
Laboratory Methods
Serum samples were tested for antibody responses to A/Cali-
fornia/4/2009 by viral microneutralization [7]. Further details
of our laboratory methods are provided in the Appendix, which
appears only in the electronic version of the journal.
Outcomes
Most individuals infected with influenza develop antibody titers
1:40 by viral microneutralization after recovery [8]. We de-
fined the H1N1 influenza seroprevalence rate as the proportion
of individuals who had antibody titers 1:40. While micro-
neutralization antibody titers 40 are not by themselves con-
clusive evidence of H1N1 influenza virus infection in all age
groups, we have assumed that the increase in cross-sectional
seroprevalence from the time period before the first wave of
pandemic influenza (hereafter, “pre–first-wave”) to the time
period after the first wave (hereafter, “post–first-wave”) is evi-
dence of recent H1N1 influenza infection. Seasonal influenza
A infection or vaccination is not typically associated with an
increase in antibody titers to H1N1 influenza [7, 9], and H1N1
influenza was the predominant circulating strain [10]. In anal-
ysis of paired serum samples, we defined the seroconversion
rate as the proportion of individuals with antibody titers of
1:10 pre–first-wave and 1:40 post–first-wave (ie, 4-fold
increase in antibody titer; titers of 1:10 were taken as 1:10
in our calculations).
The IAR was defined as the proportion of individuals infected
with H1N1 influenza during the first wave. The case-confir-
mation rate, case-hospitalization rate, case–ICU admission rate,
and case-fatality rate were defined as the proportion of H1N1
influenza infections that led to laboratory confirmation, hos-
pitalization, ICU admission, and death, respectively. Because of
containment efforts until 29 June 2009, all patients with lab-
oratory-confirmed cases were required to be hospitalized for
isolation, regardless of disease severity; therefore, only surveil-
lance data from June 30 onward were used to estimate severity
measures.
Statistical Methods
We estimated the IAR as the difference between the pre–first-
wave and post–first-wave seroprevalence rates. To validate this
approach, we compared the IAR estimates with the serocon-
version rates in paired serum samples available from a subset
of 324 blood donors aged 15–59 years. We used the estimated
IAR as the denominator for calculating the case-confirmation
 at U
niversity of H
ong K
ong on N
ovem
ber 8, 2012
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
1186 • CID 2010:51 (15 November) • Wu et al
Figure 1. Epidemiologic surveillance data for the first wave of H1N1
influenza in Hong Kong, 2009. ICU, intensive care unit.
rate, case-hospitalization rate, case–ICU admission rate, and
case-fatality rate from the e-flu surveillance data. We obtained
the posterior distributions of age-specific IARs, case-confir-
mation rates, case-hospitalization rates, case–ICU admission
rates, and case-fatality rates using Monte Carlo Markov Chain
methods with noninformative priors for all parameters. Further
details of the statistical methods are provided in the Appendix.
RESULTS
Virological surveillance data suggested that the first wave of
pandemic H1N1 influenza in Hong Kong occurred from Au-
gust to October, and evidence of infection had largely decreased
by mid-November 2009 (Figure 1). Most of the laboratory-
confirmed cases of infection in this first wave occurred in in-
dividuals aged !25 years; this age group accounted for 172%
of the laboratory-confirmed cases and hospitalizations, 32% of
ICU admissions, and 6% of deaths. Taking into account a delay
of 2–3 weeks for antibody titers to appear during convalescence
[8], we found that these virological surveillance data were con-
sistent with our serial cross-sectional seroprevalence data, which
indicated a sharp increase in seroprevalence among individuals
aged 5–25 years from September to November 2009 and a
plateau thereafter (Figure 2). This justified our decision to base
the pre–first-wave and post–first-wave seroprevalence estimates
on serum samples collected in June 2009 and November–De-
cember 2009, respectively. More than 90% of H1N1 influenza–
associated hospitalizations from 30 June through 15 November
occurred after 1 August. This justified our use of 1 August 2009
as the pre–first-wave cutoff date for our paired serum samples.
Among individuals aged 5–14 years, the seroprevalence rates
across time were similar between pediatric outpatients and pe-
diatric cohort study subjects (Figure 2). Similarly, for older age
groups, the seroprevalence rates were largely similar between
blood donors and hospital outpatients (except for those aged
20–29 years in November–December). This provided some evi-
dence that despite potential biases in our convenience sampling
scheme, the resulting serologic data provided a reasonably rep-
resentative description of seroprevalence in the community.
Prior to the first pandemic wave (June 2009), seroprevalence
was uniformly low among individuals aged 5–59 years but in-
creased substantially among younger age groups during the first
wave (Table 1 and Figure 2). Comparing the pre–first-wave and
post–first-wave seroprevalence rates (ie, the serial cross-sec-
tional method), we estimated that the IAR was 43.4% among
individuals aged 5–14 years, 15.8% among individuals aged 15–
19 years, 11.8% among individuals 20–29 years, 4.3% among
individuals aged 30–39 years, 4.6% among individuals aged 40–
49 years, and 4.0% among individuals aged 50–59 years (Table
1). These IAR estimates were broadly consistent with the IARs
estimated from seroconversion rates in paired serological anal-
ysis of blood donor samples (Appendix). Overall, we estimated
a population-weighted IAR of 10.7% (95% confidence interval
[CI], 9%–12%) among individuals aged 5–59 years through the
first wave in Hong Kong.
A total of 23,643 laboratory-confirmed H1N1 influenza cases
among individuals aged 5–59 years were reported from 29 April
through 15 November 2009. Before 30 June, 567 (67%) of the
849 laboratory-confirmed cases were isolated in hospitals as
part of containment-phase measures. These data were excluded
from our analysis of severity estimates. From 30 June onward,
hospital admission was based on medical need, and 4253 (19%)
of the 22,794 individuals aged 5–59 years with laboratory-con-
firmed H1N1 influenza were admitted to hospitals from 30
June through 15 November. There were 103 ICU admissions
and 26 deaths among patients aged 5–59 years with laboratory-
confirmed H1N1 influenza. On the basis of our estimated IAR
of 10.7% among individuals aged 5–59 years (equivalent to
597,000 cases of infection in Hong Kong), we estimated that
∼3.9% (95% CI, 3.5%–6.2%) of infections were reported and
were laboratory confirmed and that ∼0.73% (95% CI, 0.66%–
1.22%) of infected individuals required hospitalization (Table
2). The rate of ICU admissions and deaths were ∼17.6 cases
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Figure 2. Age-specific proportions of individuals with antibody titers 1:40 by viral microneutralization between June 2009 and January 2010.
Each data point corresponds to an average over multiple days, and vertical bars indicate 95% confidence intervals estimated by the exact binomial
method. Data points with sample size !10 are not shown. All subjects (151 persons aged 5–14 years) in the pediatric cohort study had antibody
titers !1:40 by viral microneutralization in April 2009 (data not shown).
Table 1. Estimated Proportion of the Population with Antibody Titers 1:40 by Viral Microneutralization against H1N1 Influenza
Virus before and after the First Wave of the Pandemic and the Estimated Infection Attack Rate
Age group,
years
Before the first wave After the first wave
Infection
attack rateab
(95% CI), %
No. of
positive
specimens/
total no.
of specimens
Percentage
positive (95% CI), % Sourcea
No. of
positive
specimens/
total no.
of specimens
Percentage
positive (95% CI), % Sourcea
5–14 0/151 0.0 (0.0–2.4) 1 183/422 43.4 (38.6–48.2) 3 43.4 (37.9–47.6)
15–19 3/97 3.1 (0.6–8.8) 2 34/180 18.9 (13.5–25.4) 4 15.8 (8.2–22.1)
20–29 12/336 3.6 (1.9–6.2) 2 135/879 15.4 (13.0–17.9) 4 11.8 (8.4–14.7)
30–39 17/302 5.6 (3.3–8.9) 2 67/676 9.9 (7.8–12.4) 4 4.3 (0.9–7.5)
40–49 10/238 4.2 (2.0–7.6) 2 45/509 8.8 (6.5–11.7) 4 4.6 (1.0–7.9)
50–59 6/352 1.7 (0.6–3.7) 2 14/247 5.7 (3.1–9.3) 4 4.0 (1.1–7.5)
Overall (5–59) 3.3 (2.8–4.7) 14 (13.0–15.4) 10.7 (9.0–12.0)
NOTE. The infection attack rate was calculated using the serial cross-sectional method. CI, confidence interval.
a Sources of specimens are as follows: (1) Pediatric cohort study, 2–29 April 2009; (2) Hong Kong Red Cross Blood Transfusion Service, 15–22 June 2009;
(3) Pediatric cohort study, 6 November to 19 December 2009; and (4) Hong Kong Red Cross Blood Transfusion Service, 1 November to 6 December 2009.
b Posterior mode.
(95% CI, 13.3–50.1 cases) and 4.4 cases (95% CI, 3.2–17 cases)
per 100,000 infections, respectively (Table 2).
Case-hospitalization rates were ∼0.47%–0.87% among in-
dividuals aged 5–59 years (Table 2 and Figure 3). Rates of H1N1
influenza–associated ICU admission were 7.9 cases (95% CI,
5.2–12.6 cases) per 100,000 infections among individuals aged
5–14 years and 75 cases (95% CI, 32.7–281 cases) per 100,000
infections among individuals aged 50–59 years. Rates of H1N1
influenza–associated mortality (case-fatality rates) followed a
similar trend, with 0.4 deaths (95% CI, 0.1–2.3 deaths) per
100,000 infections among individuals aged 5–14 years and 26.5
deaths (95% CI, 10.4–109 deaths) per 100,000 infections among
individuals aged 50–59 years. Compared with children aged 5–
14 years, adults aged 50–59 years were 9.5 and 66 times more
likely to be admitted to the ICU and die if infected, respectively.
DISCUSSION
We estimated that, during the first wave of the pandemic in
Hong Kong, 43.4% of school-aged children and 10.7% of in-
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Figure 3. Age-specific infection attack rates and severity measures of H1N1 influenza in Hong Kong. A, Pre–first-wave and post–first-wave
seroprevalence rates and infection attack rates based on the serial cross-sectional approach. B, Proportions of infections leading to laboratory confirmation,
hospitalization, intensive care unit (ICU) admission, and fatality. The points and vertical bars indicate posterior modes and 95% confidence intervals
based on the fitted model.
dividuals aged 5–59 years were infected with H1N1 influenza.
A serologic survey in England found similar IARs in London
and the West Midlands [8]. Both studies highlight the impor-
tance of including serologic surveys as a component of pandemic
surveillance. While our core results are based on data from serial
cross-sectional samples, we found similar IARs inferred from
participants from whom paired serum samples were available.
The geographically compact and homogeneously mixing pop-
ulation in the urban environment of Hong Kong permits some
degree of confidence in the validity of our IAR and severity
estimates. The detailed H1N1 influenza reporting system, the
wide coverage of the public health care system (which includes
190% of all local inpatient days [11]), and the resource in-
vestments since the epidemic of severe acute respiratory syn-
drome have led to routine laboratory testing for all patients
hospitalized with fever or pneumonia. This should allow iden-
tification of the majority of hospitalizations, ICU admissions,
and deaths directly associated with H1N1 influenza infection.
Thus, the completeness of the H1N1 influenza surveillance sys-
tem, the well-defined population denominator, and our large-
scale serologic survey provide accurate numerators and de-
nominators for the severity measures.
We based severity estimates for H1N1 influenza on the IAR
as the denominator. Some previous studies of H1N1 influenza
severity used as the denominator the clinical illness attack rate,
which depends on the probability of symptoms, as well as med-
ical care–seeking behavior of the population [3, 12]. Our es-
timated case–ICU admission rates and case-fatality rates are
broadly consistent with severity estimates using “approach 2”
of Presanis et al [3] but are ∼7–9 times lower than the estimates
using their “approach 1.” Our estimates of case-hospitalization
rates are 2–10 times higher than their Approach 2 estimates of
symptomatic case-hospitalization rate. However, the hospital-
ization-to-death ratio was 164 (4253/27) as of 15 November
in Hong Kong but was 19 (996/53) as of 14 June in New York
[3], implying that the clinical threshold for admission in terms
of disease severity at presentation may have been lower in
Hong Kong.
We estimated that ∼0.4 cases per 100,000 infections in
school-aged children led to mortality, whereas the risk of ICU
admission and death per infection was 9.5 and 66 times higher
in older adults aged 50–59 years (Figure 3). The estimates for
mortality rates in children are consistent with data from the
United Kingdom, where one study estimated a mortality rate
of 11 deaths per 100,000 symptomatic cases in children aged
5–14 years [12], while a serologic study suggested that the attack
rates had been underestimated by a factor of 10 [8]. Our es-
timates are lower than early estimates of the case-fatality rate,
but the denominators may not have been well estimated in
those studies [1, 13, 14]. Previously, a statistical model was used
to estimate that the excess number of deaths due to seasonal
influenza in Hong Kong was 11.8 deaths (95% CI, 3.8–20.1
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deaths) per 100,000 population aged 40–64 years [15]. Assum-
ing an annual IAR of 20%, this estimate would translate into
59 deaths (95% CI, 19–101 deaths) per 100,000 infections,
which is slightly larger than our H1N1 influenza case-fatality
rate estimate of 18 deaths (95% CI, 9–74 deaths) per 100,000
infections among individuals aged 40–59 years. This supports
the prevailing view that H1N1 influenza is not more severe
than seasonal influenza in terms of morbidity and mortality.
Simulation studies have suggested that administration of
pandemic vaccines to school-aged children provides substantial
benefits to the community [16, 17]. However, since 43.4% of
school-aged children were infected in the first wave and are
likely immune to reinfection, and infections in school-age chil-
dren are rarely severe (Table 2), there may be less justification
to include this age group as a target group for vaccination after
the first wave of the pandemic in Hong Kong. Furthermore,
given the substantial attack rate in children during the first
wave, we speculate that a large second wave may be unlikely
to occur unless there is substantial antigenic drift. So far, there
has been no evidence of the emergence of antigenically drifted
H1N1 influenza viruses [18].
Our study has a number of limitations. First, we have used
antibody titers 1:40 measured by viral microneutralization
as an indicator of recent infection, correcting for baseline (pre-
existing) seroprevalence levels, but this may lead to underes-
timation of the IAR if not all infections led to antibody titers
1:40, or if some individuals with baseline titers 1:40 were
infected. Another study found that ∼5% of laboratory-con-
firmed H1N1 influenza cases did not develop convalescent an-
tibody titers 11:40 measured by hemagglutinin inhibition test-
ing [8]. Second, our estimates of the IAR would be biased
upward if infection with other circulating influenza viruses led
to cross-reactive antibody responses resulting in antibody titers
1:40. However, from August through October 2009, 83% of
influenza A viruses detected in Hong Kong were H1N1, and
only 3% of isolated viruses were seasonal H1N1 viruses, which
are more likely to be associated with cross-serological cross
reactions with H1N1 virus (Appendix) [10]. Third, a minority
of severe illnesses associated with H1N1 influenza infection
might not be identified by molecular detection methods—for
example, if admission occurred after cessation of viral shedding
associated with the primary infection; thus, we may have un-
derestimated the pandemic disease burden. We did not have
seroepidemiological data from individuals aged 160 years and
consequently cannot comment on attack rates or complication
rates in this important age group. Finally, our analyses are
primarily based on seroprevalence among blood donors to the
Hong Kong Red Cross, who may not be representative of the
whole population. We do not have detailed data on donors to
compare their risk of infection with the general population,
but we did observe very similar seroprevalence rates across the
3 groups of subjects in our study—that is, blood donors, hos-
pital outpatients, and participants in a community cohort (Fig-
ure 2 and Figure 2A in the Appendix ).
We chose to use microneutralization tests rather than he-
magglutination inhibition tests, following preliminary stud-
ies that showed that microneutralization was more sensitive
than hemagglutination inhibition for detection of antibody re-
sponses in H1N1 influenza infection [7, 8]. There is only limited
cross-reactivity between pandemic and recent seasonal H1N1
influenza viruses by the microneutralization test (used in this
study), but there is some cross-reaction in individuals, increas-
ing with age and particularly noticeable in those aged 165 years
[8, 9]. Thus, in a given individual, current serological methods
do not conclusively distinguish between antibody resulting
from pandemic H1N1 influenza infection from cross-reactive
antibody arising from prior infections with seasonal H1N1 in-
fluenza, especially in those aged 160 years, which is one reason
why we did not address the infection rates or disease severity
in elderly individuals. Our study design is based on the differ-
ence in age-stratified seroprevalence in the pre–first-wave pe-
riod versus the post–first-wave period, a time when there was
minimal seasonal H1N1 influenza virus circulation in Hong
Kong. Thus, our conclusions for individuals aged !60 years
are unlikely to be confounded by issues pertaining to serologi-
cal cross-reactivity. While immune senescence could potentially
lead to an underestimation of attack rates in elderly individuals,
especially those aged 165 years, this is unlikely to affect our
study, which investigated individuals aged !60 years.
In conclusion, ∼10.7% of the population aged 5–59 years
and half of all school-aged children in Hong Kong were infected
during the first wave of pandemic H1N1 influenza. Compared
with school children aged 5–14 years, older adults aged 50–59
years, although less likely to acquire infection, had 9.5 and 66
times higher risk of ICU admission and death if infected. Thus,
the apparently low morbidity and mortality burden of 2009
pandemic H1N1 influenza, despite an IAR in the first wave
similar to that of a seasonal epidemic, appears to be caused by
low infection rates in older adults, who faced a much greater
risk of severe illness if infected. The reasons why older adults
appear relatively resistant to H1N1 influenza infection, even
though they appear to lack neutralizing antibody, remain un-
clear. If antigenic drift or other adaptation of the H1N1 influ-
enza virus allows these older age groups to be infected more
efficiently, the morbidity and mortality of subsequent waves of
the pandemic could yet become substantial.
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